Withings, a global leader in connected health, today unveiled BeamO1 – a disruptive 4-in-1 health checkup device. This advanced “multiscope” will place the ability to measure core health vitals taken during physician visits into the palm of the hand and will become available in the United States following FDA Clearance. For the first time, BeamO will combine ECG, oximeter, stethoscope, and thermometer sensors to turn the humble thermometer into a powerful tool for regular monitoring of heart and lung health. Portable and smaller than a smartphone, it is designed to help individuals and families perform at-home checkups and to substantially improve the quality of telehealth visits.
“BeamO is a transformative multiscope device. Once, body temperature was the only health scan routinely taken at home. BeamO will revolutionize the measurement of the core vitals carried out during medical visits from the comfort of one’s own home. This crucial data will provide a vital overview of overall health or warning signs of potential areas of concern. Instead of measuring these stats a couple of times a year in a clinical setting, it will be possible to assess them every day.” Said Eric Carreel, Founder and President of Withings. “BeamO will be the thermometer of the future, providing the ability to assess temperature and observe the state of the heart and lungs.”
“Post-pandemic telemedicine is commonplace. While convenient and cost-effective, remote visits lacked the ability for health professionals to carry out the routine checks they perform in person. BeamO will make this possible remotely with a device that combines the functionality of four different pieces of medical equipment.” Carreel continued.
Powerful Health Scan Powered by Multiscope Analysis
BeamO is packed with sensors that beam light waves to interpret blood flow patterns and temperature, as well as acoustic information. It performs multiple functions in one handheld device:
With these capabilities, BeamO will conduct a 4-in-1 health checkup of body temperature, heart, and lung health in under a minute. It will be able to alert users to possible fever and infection and will detect possible cardiovascular issues, including atrial fibrillation (AfiB) (following FDA clearance), which is one of the most prevalent forms of arrhythmias, and provides alerts in case heart rates are abnormal2.
A Complete Health Record, Secured
By automatically syncing with the Withings app through Wi-Fi, BeamO creates comprehensive health records over time. To better track individual and family health journeys, Withings also introduces new capabilities within the Withings App for BeamO and its entire family of connected health products.
It makes it even easier to track health stats over time that can be recorded and shared. With the Withings app, users can view their full history of health readings along with interpretations of their meanings and actionable advice. Family medical health history can also be uploaded and, where necessary, shared with physicians and other family members. It also allows multiple family members to create individual profiles to use and share Withings devices.
In addition, for the first time, the Withings App allows users to upload details of any medications they are taking, set alerts and reminders to administer at the appropriate times, and log usage and side effects that can be shared with doctors to manage dosage and effectiveness.
A CES Innovations Award Honoree, BeamO will be demoed during CES at the Withings Booth (LVCC NH #8637). BeamO will retail at $249.95 in June 2024, following FDA clearance of its ECG capability2.
Withings created the first smart scale in 2009 and has been the pioneer in connected health ever since. Its clinically validated and multi-award-winning range is used by millions worldwide and includes smart scales, hybrid watches, blood pressure monitors, sleep analyzers, and more. The team of engineers, data scientists, and healthcare professionals at Withings work alongside clinical experts to make it possible to take medical-grade measurements at home. Withings was the first to bring measurements for pulse wave velocity and electrodermal activity into the home – finding ever more precise ways to measure our health. Withings Health Solutions, its dedicated division serving healthcare professionals across chronic disease prevention and management, remote patient monitoring, clinical research, and more, helps bridge the gap between patients and their care teams.
Withings is dedicated to creating a world where people can see their path to better health and feel supported to pursue it using devices designed to fit beautifully into daily life, supported by information that unlocks long-term health insights and offers programs to create meaningful change. Find out more at withings.com and connect with us on Facebook, Instagram, or X.
Withings UK & North American Media Contact:
Ian Twinn / Tandem Marketing Communications
1 This device is not yet available for sale or distribution in the US as its effectiveness and safety have not been reviewed by the US FDA. Caution: Investigational Device, Limited by Federal or United States.
2 CAUTION Investigational device. Limited by Federal (or United States) law to investigational use. Not for sale or distribution. The features of this device are subject to change depending on the regulatory clearance/approvals.
Keep up with industry news, trends, investment activity, and job openings — in one weekly newsletter.